

M. Sakanaka, et al.
U.S.S.N. 09/913,669
Page 2

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1-31. (Cancelled).

32. (Currently Amended) A method of treating a patient suffering from a ~~for the treatment of diseases caused by traumatic or compression injuries to~~ injury of a nervous ~~tissue~~ tissues, the method ~~comprising~~ comprises the step of administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising a therapeutic agent selected from ginsenoside Rb₁, its metabolites and salts thereof.

33. (Currently Amended) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition is capable of suppressing the ~~suppresses~~ secondary degeneration of the injured nervous tissue ~~tissues caused by traumatic or compression injuries to the nervous tissues.~~

34. (Currently Amended) The method of claim 33, wherein the nervous ~~tissues are spinal cord~~ tissue is a spinal cord.

35. (Currently Amended) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition ameliorates ~~agent is capable ameliorating~~ paralysis or paraplegia caused by ~~traumatic or compression injuries the~~ injury to the nervous tissue ~~tissue.~~

36. (Currently Amended) The method of claim 35, wherein the nervous ~~tissues are spinal cord~~ tissue is a spinal cord.

BOS2 499194_1/

M. Sakanaka, et al.
U.S.S.N. 09/913,669
Page 3

37. (Cancelled).

38 (Currently Amended) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition is capable of suppressing the suppresses secondary degeneration of the nervous tissues caused by demyelination.

39. (Currently Amended) The method of claim 38, wherein the therapeutically effective amount of the pharmaceutical composition is capable of suppressing suppresses apoptosis or apoptosis-like cell death of oligodendrocytes.

40. (Previously Presented) The method of claim 32, wherein the pharmaceutical composition is administered intravenously to the patient.

41. (Previously Presented) The method of claim 32, wherein the pharmaceutical composition is administered in a single intravenous infusion or in a continuous intravenous infusion to the patient.

42. (Currently Amended) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition administered to the patient provides a concentration of 1 ng/ml or less of ginsenoside Rb₁, its metabolites or salts thereof ~~to in~~ the extracellular fluid ~~in of a lesion at a concentration of 1 ng/ml or less.~~

43. (Currently Amended) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition administered to the patient provides a concentration of 1 pg/ml or less of ginsenoside Rb₁, its metabolites or salts thereof ~~to in~~ the extracellular fluid ~~in of a lesion at a concentration of 1 pg/ml or less.~~

BOS2, 499194_17

M. Sakanaka, et al.
U.S.S.N. 09/913,669
Page 4

44. (Currently Amended) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition administered to the patient provides a concentration of 100 fg/ml or less of ginsenoside Rb₁, its metabolites or salts thereof ~~to in~~ the extracellular fluid ~~in of a lesion at a concentration of 100 fg/ml or less.~~

45-51. (Cancelled).

52. (Currently Amended) The method of claim 32, wherein the ~~diseases caused by~~ traumatic or compression injuries to the nervous tissue of the patients ~~comprise cause~~ spinal cord injury, head injury, neurotrauma, cerebral hemorrhage, subarachnoid hemorrhage, peripheral nerve injuries, Parkinson's Disease, demyelinating diseases, retinal detachment, herniation of intervertebral disks, spinal canal stenosis, spondylolysis, slipping diseases, cervical spondylolysis, ossification of the posterior longitudinal ligament or facial nerve paralysis.

53. (Previously Presented) The method of claim 32, wherein the nervous tissues are spinal cords.

BOS2_499194_1/